Ramalingam SS, Vansteenkiste J, Planchard D, et al. - Researchers randomized 556 people with formerly untreated advanced non-small cell lung cancer (NSCLC) with an EGFR mutation to receive either once-daily 80-mg osimertinib or one of two other tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI; once-daily 250-mg gefitinib or once-daily 150-mg erlotinib). Individuals receiving these drugs were combined in a single comparator group in order to determine overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. Compared with those who received a comparator EGFR-TKI, longer overall survival was observed in those who received osimertinib. Irrespective of a longer duration of exposure in the osimertinib group, the safety profile for osimertinib was comparable to that of the comparator EGFR-TKIs.